BACKGROUND:Cocaine's increase of dopamine is strongly associated with its reinforcing properties and, thus, agents that reduce dopamine have received much attention as candidate cocaine-dependence treatments. The potential efficacy of reserpine, a dopamine depletor, for treating cocaine dependence is suggested by both pre-clinical research and a small clinical trial. METHOD:One hundred and nineteen participants who met DSM-IV criteria for cocaine dependence were enrolled into this 12-week, double-blind, placebo-controlled outpatient trial. Participants received either reserpine (0.5 mg/day) or matching placebo. All participants received 1h of manualized individual cognitive behavioral therapy on a weekly basis. Outcome measures included cocaine use as determined by self-report confirmed with urine benzoylecgonine results, cocaine craving, addiction severity index scores, and clinical global impression scores. Safety measures included adverse events, EKGs, vital signs, laboratory tests, and the Hamilton Depression Inventory. RESULTS:Seventy-nine participants (i.e., 66%) completed the 12-week trial. The safety results suggest that reserpine was safe and well tolerated by the participants. The efficacy measures indicated no significant differences between reserpine and placebo. CONCLUSION: These results do not support the efficacy of reserpine as a cocaine-dependence treatment.
RCT Entities:
BACKGROUND:Cocaine's increase of dopamine is strongly associated with its reinforcing properties and, thus, agents that reduce dopamine have received much attention as candidate cocaine-dependence treatments. The potential efficacy of reserpine, a dopamine depletor, for treating cocaine dependence is suggested by both pre-clinical research and a small clinical trial. METHOD: One hundred and nineteen participants who met DSM-IV criteria for cocaine dependence were enrolled into this 12-week, double-blind, placebo-controlled outpatient trial. Participants received either reserpine (0.5 mg/day) or matching placebo. All participants received 1h of manualized individual cognitive behavioral therapy on a weekly basis. Outcome measures included cocaine use as determined by self-report confirmed with urine benzoylecgonine results, cocaine craving, addiction severity index scores, and clinical global impression scores. Safety measures included adverse events, EKGs, vital signs, laboratory tests, and the Hamilton Depression Inventory. RESULTS: Seventy-nine participants (i.e., 66%) completed the 12-week trial. The safety results suggest that reserpine was safe and well tolerated by the participants. The efficacy measures indicated no significant differences between reserpine and placebo. CONCLUSION: These results do not support the efficacy of reserpine as a cocaine-dependence treatment.
Authors: Adam Bisaga; Efrat Aharonovich; Wendy Y Cheng; Frances R Levin; John J Mariani; Wilfrid N Raby; Edward V Nunes Journal: Drug Alcohol Depend Date: 2010-05-26 Impact factor: 4.492
Authors: Madhukar H Trivedi; Tracy L Greer; Chad D Rethorst; Thomas Carmody; Bruce D Grannemann; Robrina Walker; Diane Warden; Kathy Shores-Wilson; Mark Stoutenberg; Neal Oden; Meredith Silverstein; Candace Hodgkins; Lee Love; Cindy Seamans; Angela Stotts; Trey Causey; Regina P Szucs-Reed; Paul Rinaldi; Hugh Myrick; Michele Straus; David Liu; Robert Lindblad; Timothy Church; Steven N Blair; Edward V Nunes Journal: J Clin Psychiatry Date: 2017 Sep/Oct Impact factor: 4.384
Authors: Neal L Oden; Paul C VanVeldhuisen; Paul G Wakim; Madhukar H Trivedi; Eugene Somoza; Daniel Lewis Journal: Am J Drug Alcohol Abuse Date: 2011-09 Impact factor: 3.829
Authors: Sharon L Walsh; Lisa S Middleton; Conrad J Wong; Paul A Nuzzo; Charles L Campbell; Craig R Rush; Michelle R Lofwall Journal: Drug Alcohol Depend Date: 2012-11-28 Impact factor: 4.492
Authors: Ryoko Susukida; Rosa M Crum; Hwanhee Hong; Elizabeth A Stuart; Ramin Mojtabai Journal: Int J Methods Psychiatr Res Date: 2018-02-21 Impact factor: 4.182